These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2653016)

  • 61. A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusions.
    Leizorovicz A; Durrieu G; Boissel JP
    Drugs; 1987; 33 Suppl 3():133-7. PubMed ID: 3315579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
    Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ
    Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction.
    Munger MA; Forrence EA
    Clin Pharm; 1990 Jul; 9(7):530-40. PubMed ID: 2198125
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Coronary thrombolysis after intracoronary and intravenous administration of streptokinase to myocardial infarct patients].
    Dorogun BN; Smirnov AA; Dobrovol'skiĭ AB; Pomerantsev EV; Staroverov II
    Kardiologiia; 1987 Mar; 27(3):9-14. PubMed ID: 3586489
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Limitation of myocardial infarct size and preservation of left ventricular function by early administration of APSAC in myocardial infarction.
    Bassand JP; Machecourt J; Cassagnes J; Lusson JR; Borel E; Schiele F
    Am J Cardiol; 1989 Jul; 64(2):18A-23A; discussion 24A-26A. PubMed ID: 2662738
    [TBL] [Abstract][Full Text] [Related]  

  • 66. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 67. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance.
    Gemmill JD; Hogg KJ; Douglas JT; Dunn FG; Lowe GD; Rae AP; Hillis WS
    Eur Heart J; 1993 Jun; 14(6):819-25. PubMed ID: 8325311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
    Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK
    Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
    Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
    Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Coronary thrombolysis in acute myocardial infarction. Initial experience with an intravenous thrombolytic agent].
    Martínez Ríos MA; Cárdenas M; Gil M; Iturbe I; Alarcón A; Soní J
    Arch Inst Cardiol Mex; 1984; 54(1):3-9. PubMed ID: 6372717
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Summary of U.S. clinical trials program for evaluation of anistreplase.
    Anderson JL
    Clin Cardiol; 1990 Mar; Suppl 5():V33-8; discussion V67-72. PubMed ID: 2182239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study.
    Julian DG
    Am J Cardiol; 1989 Jul; 64(2):27A-29A; discussion 41A-42A. PubMed ID: 2662740
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
    Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
    Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC.
    Hoffmann JJ; Vijgen M
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):279-84. PubMed ID: 1716481
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography.
    Kennedy JW; Gensini GG; Timmis GC; Maynard C
    Am J Cardiol; 1985 Apr; 55(8):871-7. PubMed ID: 3885707
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systemic markers of fibrinolysis after unsuccessful intracoronary streptokinase thrombolysis for acute myocardial infarction. Does nonreperfusion indicate failure to achieve a systemic lytic state?
    White CW; Schwartz JL; Ferguson DW; Brayden GP; Kelly KJ; Kioschos JM; Marcus ML
    Am J Cardiol; 1984 Oct; 54(7):712-7. PubMed ID: 6486019
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase.
    Vila V; Regañón E; Aznar J; Lacueva V; Ruano M; Laiz B
    Thromb Res; 1990 Mar; 57(5):783-94. PubMed ID: 2339369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.